Our mission at Infinity Bio is to provide our customers with high quality, cost effective and timely antibody profiling services that are unparalleled in the industry.
The staggering complexity of each antibody repertoire carries a wealth of information about past and ongoing immune responses that are intimately connected with human and animal health. Decoding the complex interactions between an individual's circulating antibodies and reactive antigens is revolutionizing our understanding of diseases and personalized responses to various therapeutics.
Our scientific cofounders, H. Benjamin Larman, PhD, Stephen J. Elledge, PhD, and Joel J. Credle, PhD, have created MIPSA, the first technology that truly meets the diverse needs of researchers and clinicians seeking to characterize the immune responses of their study participants and patients. Our commercial team has deep experiences providing complex molecular assay services at scale, employing best practices in quality assurance, supplying insight-driving computational analyses in a secure cloud environment, and working with customers to make sure their study goals are not only met, but exceeded.
Get in touch today to find out how Infinity Bio can partner with you to unlock insights of the immune system by profiling antibodies with MIPSA.